slug large_stringlengths 3 19 | name large_stringlengths 6 57 | source_index int64 0 9 | source_text large_stringlengths 76 356 | doi large_stringlengths 13 34 | resolved large_stringclasses 1
value | verified_title large_stringlengths 24 202 |
|---|---|---|---|---|---|---|
5-amino-1mq | 5-Amino-1MQ (NNMT inhibitor) | 0 | Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508:258-262 (target validation; genetic, not 5A1MQ). | 10.1038/nature13198 | high | Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity |
adipotide | Adipotide (FTPP / Prohibitin-TP01) | 0 | Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004;10(6):625-632 (PMID 15133506) — the foundational paper. | 10.1038/nm1048 | high | Reversal of obesity by targeted ablation of adipose tissue |
adipotide | Adipotide (FTPP / Prohibitin-TP01) | 1 | Barnhart KF, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011 (the ~11%/28-day primate result + renal-tubular signal). | 10.1126/scitranslmed.3002621 | high | A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys |
adipotide | Adipotide (FTPP / Prohibitin-TP01) | 2 | Rupnick MA, et al. Adipose tissue mass can be regulated through the vasculature. PNAS. 2002 (proof-of-concept). | 10.1073/pnas.162349799 | high | Adipose tissue mass can be regulated through the vasculature |
afamelanotide | Afamelanotide (Scenesse / Melanotan-1) | 3 | Wensink D, et al. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert Rev Clin Pharmacol. 2021 (review). | 10.1080/17512433.2021.1879638 | high | Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria |
ahk-cu | AHK-Cu (Copper Tripeptide-3) | 0 | Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834–839. (PMID 17703734) — the foundational ex-vivo/in-vitro study. | 10.1007/bf02978833 | high | The effect of tripeptide-copper complex on human hair growth in vitro |
aicar | AICAR (Acadesine) | 0 | Narkar VA, et al. AMPK and PPARδ Agonists Are Exercise Mimetics. Cell. 2008;134:405-415 (the ~44% endurance / "exercise mimetic" paper; Evans lab, Salk). | 10.1016/j.cell.2008.06.051 | high | AMPK and PPARδ Agonists Are Exercise Mimetics |
alpha-arbutin | Alpha Arbutin | 0 | Tantanasrigul P, Sripha A, Chongmelaxme B. The Efficacy of Topical Cosmetic Containing Alpha-Arbutin 5% and Kojic Acid 2% Compared With Triple Combination Cream for the Treatment of Melasma: A Split-Face, Evaluator-Blinded Randomized Pilot Study. J Cosmet Dermatol. 2024;e16562. | 10.1111/jocd.16562 | high | The Efficacy of Topical Cosmetic Containing Alpha-Arbutin 5% and Kojic Acid 2% Compared With Triple Combination Cream for the Treatment of Melasma: A Split-Face, Evaluator-Blinded Randomized Pilot Study |
alpha-arbutin | Alpha Arbutin | 1 | Sugimoto K, Nishimura T, Nomura K, Sugimoto K, Kuriki T. Inhibitory Effects of Alpha-Arbutin on Melanin Synthesis in Cultured Human Melanoma Cells and a Three-Dimensional Human Skin Model. Biol Pharm Bull. 2004;27(4):510-514. | 10.1248/bpb.27.510 | high | Inhibitory Effects of Alpha-Arbutin on Melanin Synthesis in Cultured Human Melanoma Cells and a Three-Dimensional Human Skin Model |
alpha-arbutin | Alpha Arbutin | 2 | Boo YC. Arbutin as a Skin Depigmenting Agent with Antimelanogenic and Antioxidant Properties. Antioxidants (Basel). 2021;10(7):1129. | 10.3390/antiox10071129 | high | Arbutin as a Skin Depigmenting Agent with Antimelanogenic and Antioxidant Properties |
amycretin | Amycretin | 1 | Dahl K, et al. Amycretin, a novel unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: a Phase 1b/2a study. Lancet. 2025. | 10.1016/s0140-6736(25)01185-7 | high | Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study |
argireline | Argireline (Acetyl Hexapeptide-8) | 0 | Blanes-Mira C, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002. | 10.1046/j.1467-2494.2002.00153.x | high | A synthetic hexapeptide (Argireline) with antiwrinkle activity |
argireline | Argireline (Acetyl Hexapeptide-8) | 3 | Lim S-H, et al. Enhanced skin permeation of anti-wrinkle peptides via molecular modification. (penetration limits.) PMC5785486. | 10.1038/s41598-017-18454-z | high | Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification |
argireline | Argireline (Acetyl Hexapeptide-8) | 4 | Public interest in acetyl hexapeptide-8: longitudinal analysis. PMC10915729. | 10.2196/54217 | high | Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis |
azelaic-acid | Azelaic Acid | 0 | King S, Campbell J, Rowe R, Daly ML, Moncrieff G, Maybury C. A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging. J Cosmet Dermatol. 2023;22(10):2650-2662. | 10.1111/jocd.15923 | high | A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging |
azelaic-acid | Azelaic Acid | 1 | Albzea W, AlRashidi R, Alkandari D, et al. Azelaic Acid Versus Hydroquinone for Managing Patients With Melasma: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2023;15(7):e41796. | 10.7759/cureus.41796 | high | Azelaic Acid Versus Hydroquinone for Managing Patients With Melasma: Systematic Review and Meta-Analysis of Randomized Controlled Trials |
azelaic-acid | Azelaic Acid | 2 | McKesey J, Tovar-Garza A, Pandya AG. Melasma Treatment: An Evidence-Based Review. Am J Clin Dermatol. 2020;21(2):173-225. | 10.1007/s40257-019-00488-w | high | Melasma Treatment: An Evidence-Based Review |
bakuchiol | Bakuchiol | 0 | Chaudhuri RK, Bojanowski K. Bakuchiol: a retinol-like functional compound revealed by gene expression profiling and clinically proven to have anti- aging effects. Int J Cosmet Sci. 2014; 36(3):221-30. doi:10.1111/ics.12117. [Sytheon Ltd — declared conflict of interest] | 10.1111/ics.12117 | high | Bakuchiol: a retinol‐like functional compound revealed by gene expression profiling and clinically proven to have anti‐aging effects |
bakuchiol | Bakuchiol | 1 | Dhaliwal S, Rybak I, Ellis SR, et al. Prospective, randomized, double- blind assessment of topical bakuchiol and retinol for facial photoageing. Br J Dermatol. 2019; 180(2):289-296. doi:10.1111/bjd.16918. [Independent — University of California / Michigan / Florida / Pennsylvania] | 10.1111/bjd.16918 | high | Prospective, randomized, double‐blind assessment of topical bakuchiol and retinol for facial photoageing |
bakuchiol | Bakuchiol | 2 | Draelos ZD, Gunt H, Zeichner J, Levy S. Clinical evaluation of a nature- based bakuchiol anti-aging moisturizer for sensitive skin. J Drugs Dermatol. 2020; 19(12):1181. | 10.36849/jdd.2020.5522 | high | Clinical Evaluation of a Nature-Based Bakuchiol Anti-Aging Moisturizer for Sensitive Skin |
bakuchiol | Bakuchiol | 3 | Goldberg DJ, Robinson DM, Granger C. Clinical evidence of the efficacy and safety of a new 3-in-1 anti-aging topical night serum-in-oil containing melatonin, bakuchiol, and ascorbyl tetraisopalmitate. J Cosmet Dermatol. 2020. | 10.1111/jocd.12896 | high | Clinical evidence of the efficacy and safety of a new 3‐in‐1 anti‐aging topical night serum‐in‐oil containing melatonin, bakuchiol, and ascorbyl tetraisopalmitate: 103 females treated from 28 to 84 days |
bakuchiol | Bakuchiol | 6 | Chaudhuri RK. Chapter — Bakuchiol: A Retinol-Like Functional Compound, Modulating Multiple Retinol and Non-Retinol Targets. In: Cosmeceuticals and Active Cosmetics. 2015. [Sytheon — mechanistic review] | 10.1201/b18895-2 | high | Bakuchiol: A Retinol-Like Functional Compound, Modulating Multiple Retinol and Non-Retinol Targets |
bimagrumab | Bimagrumab (BYM338) | 0 | Heymsfield SB, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type-2 diabetes and obesity: a Phase 2 randomized clinical trial. JAMA Netw Open. 2021. | 10.1001/jamanetworkopen.2020.33457 | high | Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity |
bimagrumab | Bimagrumab (BYM338) | 2 | Nunn E, et al. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Mol Metab. 2024. | 10.1016/j.molmet.2024.101880 | high | Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism |
bpc-157 | BPC-157 | 1 | Chang C-H, et al. Pentadecapeptide BPC 157 enhances growth-hormone-receptor expression in tendon fibroblasts. 2014. | 10.3390/molecules191119066 | high | Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts |
bpc-157 | BPC-157 | 2 | Hsieh M-J, et al. Therapeutic potential of pro-angiogenic BPC157 associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. | 10.1007/s00109-016-1488-y | high | Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation |
bpc-157 | BPC-157 | 4 | Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: a Systematic Review. 2025. — 544 articles screened → 36 included (35 preclinical, 1 clinical). | 10.1177/15563316251355551 | high | Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review |
ceramides | Ceramides | 0 | Elias PM, Wakefield JS. Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol. 2014. | 10.1016/j.jaci.2014.05.048 | high | Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis |
ceramides | Ceramides | 1 | Meckfessel MH, Brandt S. The structure, function, and importance of ceramides in skin and their use as therapeutic agents in skin-care products. J Am Acad Dermatol. 2014; 71(1):177-84. | 10.1016/j.jaad.2014.01.891 | high | The structure, function, and importance of ceramides in skin and their use as therapeutic agents in skin-care products |
ceramides | Ceramides | 3 | Spada F, Barnes TM, Greive KA. Skin hydration is significantly increased by a cream formulated to mimic the skin's own natural moisturizing systems. Clin Cosmet Investig Dermatol. 2018. | 10.2147/ccid.s177697 | high | Skin hydration is significantly increased by a cream formulated to mimic the skin’s own natural moisturizing systems |
cerebrolysin | Cerebrolysin | 0 | Cochrane reviews — Cerebrolysin for vascular dementia (2013; updated 2025) and for acute ischemic stroke (2023, 7 RCTs / 1,773 participants: no mortality benefit; ↑ non-fatal serious AEs RR ~2.39). | 10.1002/14651858.cd008900.pub2 | high | Cerebrolysin for vascular dementia |
dasatinib-quercetin | Dasatinib + Quercetin / Fisetin (Senolytics) | 0 | Zhu Y, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 2015 (D+Q discovery; SCAP hypothesis). | 10.1111/acel.12344 | high | The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs |
dasatinib-quercetin | Dasatinib + Quercetin / Fisetin (Senolytics) | 1 | Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med 2020 (D, Q, Fisetin, Navitoclax as first senolytics). | 10.1111/joim.13141 | high | Senolytic drugs: from discovery to translation |
dasatinib-quercetin | Dasatinib + Quercetin / Fisetin (Senolytics) | 3 | Yousefzadeh MJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 2018 (top flavonoid; mouse lifespan). | 10.1016/j.ebiom.2018.09.015 | high | Fisetin is a senotherapeutic that extends health and lifespan |
ectoin | Ectoin | 0 | Graf R, et al. The multifunctional role of ectoine as a natural cell protectant. Clin Dermatol. 2008; 26(4):326-33. | 10.1016/j.clindermatol.2008.01.002 | high | The multifunctional role of ectoine as a natural cell protectant |
ectoin | Ectoin | 1 | Marini A, et al. Ectoine-containing cream in the treatment of mild to moderate atopic dermatitis: a randomised, comparator-controlled, intra-individual double-blind, multi-center trial. Skin Pharmacol Physiol. 2014. | 10.1159/000351381 | high | Ectoine-Containing Cream in the Treatment of Mild to Moderate Atopic Dermatitis: A Randomised, Comparator-Controlled, Intra-Individual Double-Blind, Multi-Center Trial |
ectoin | Ectoin | 3 | Bilstein A, et al. Ectoin in the Treatment of Irritations and Inflammations of the Eye Surface. Biomed Res Int. 2021. | 10.1155/2021/8885032 | high | Ectoine in the Treatment of Irritations and Inflammations of the Eye Surface |
ectoin | Ectoin | 4 | Kauth M, Trusova O. Topical Ectoine Application in Children and Adults to Treat Inflammatory Diseases Associated with an Impaired Skin Barrier: A Systematic Review. Dermatol Ther (Heidelb). 2022. | 10.1007/s13555-021-00676-9 | high | Topical Ectoine Application in Children and Adults to Treat Inflammatory Diseases Associated with an Impaired Skin Barrier: A Systematic Review |
epitalon | Epitalon (Epithalon) | 0 | Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003. | 10.1023/a:1025493705728 | high | Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells |
epitalon | Epitalon (Epithalon) | 2 | Araj (et al.). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. (independent in-vitro study) | 10.1007/s10522-025-10315-x | high | Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity |
follistatin | Follistatin (FST-344) | 2 | Kota J, Sumner CJ, et al. Inhibition of myostatin, with emphasis on follistatin as a therapy for muscle disease. (Review; PMC2717722.) | 10.1002/mus.21244 | high | Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease |
ghk-cu | GHK-Cu (Copper Tripeptide-1) | 4 | Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide (gene-expression review). Int J Mol Sci. 2018 (PMID 29986520). | 10.3390/ijms19071987 | high | Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data |
ghk-cu | GHK-Cu (Copper Tripeptide-1) | 5 | Mortazavi SM, et al. Topically applied GHK as an anti-wrinkle peptide: advantages, problems, prospects. BioImpacts. 2024. | 10.34172/bi.30071 | high | Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective |
ghrp-6 | GHRP-6 | 2 | Kojima M, Kangawa K, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999. (the endogenous ligand GHRP-6 pointed to) | 10.1038/45230 | high | Ghrelin is a growth-hormone-releasing acylated peptide from stomach |
glutathione | Glutathione (GSH) | 0 | Sonthalia S, et al. Glutathione as a skin whitening agent: facts, myths, evidence and controversies. Indian J Dermatol Venereol Leprol. 2016 (mechanism, evidence, Philippine FDA warning). | 10.4103/0378-6323.179088 | high | Glutathione as a skin whitening agent: Facts, myths, evidence and controversies |
glutathione | Glutathione (GSH) | 1 | Glutathione for skin lightening: a regnant myth or evidence-based verity? (PMC5808366) — oral GRAS status, low bioavailability, IV controversy. | 10.5826/dpc.0801a04 | high | Glutathione for skin lightening: a regnant myth or evidence-based verity? |
hexarelin | Hexarelin (Examorelin) | 0 | Bodart V, Ong H, et al. CD36 mediates the cardiovascular action of growth-hormone-releasing peptides in the heart. Circ Res. 2002. (CD36 identification) | 10.1161/01.res.0000016164.02525.b4 | high | CD36 Mediates the Cardiovascular Action of Growth Hormone-Releasing Peptides in the Heart |
humanin | Humanin (HN / HNG / S14G-Humanin) | 0 | Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ. PNAS. 2001 (original discovery). | 10.1073/pnas.101133498 | high | A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ |
hyaluronic-acid | Hyaluronic Acid (Sodium Hyaluronate) | 2 | Nobile V, et al. Oral intake and topical application of hyaluronic acid ameliorates skin aging signs: efficacy results of a placebo-controlled in&out trial. Cosmetics. 2025; 12:52. | 10.3390/cosmetics12020052 | high | Oral Intake and Topical Application of Hyaluronic Acid Ameliorates Skin Aging Signs: Efficacy Results of a Placebo-Controlled In&Out Trial |
hyaluronic-acid | Hyaluronic Acid (Sodium Hyaluronate) | 3 | Oral sodium hyaluronate improves skin hydration, barrier function and signs of aging: a randomized, double-blind, placebo-controlled trial in 150 healthy adults. Sci Rep. 2025. | 10.1038/s41598-025-32758-5 | high | Oral sodium hyaluronate improves skin hydration, barrier function and signs of aging: a randomized, double-blind, placebo-controlled trial in 150 healthy adults |
hyaluronic-acid | Hyaluronic Acid (Sodium Hyaluronate) | 5 | Zhang R, Yaqoubi M, et al. The Effect of Local Hyaluronic Acid Injection on Skin Aging: A Systematic Review and Meta-Analysis. J Cosmet Dermatol. 2024; PMC11731322. | 10.1111/jocd.16760 | high | The Effect of Local Hyaluronic Acid Injection on Skin Aging: A Systematic Review and Meta‐Analysis |
ipamorelin | Ipamorelin | 0 | Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. (PMID 9849822) | 10.1530/eje.0.1390552 | high | Ipamorelin, the first selective growth hormone secretagogue |
ipamorelin | Ipamorelin | 2 | Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020. | 10.1002/rco2.9 | high | Growth hormone secretagogues: history, mechanism of action, and clinical development |
kojic-acid | Kojic Acid | 0 | Deo KS, Dash KN, Sharma YK, Virmani NC, Oberai C. Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study of Efficacy and Safety. Indian J Dermatol. 2013;58(4):281-285. | 10.4103/0019-5154.113940 | high | Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study of Efficacy and Safety |
kojic-acid | Kojic Acid | 2 | Saeedi M, Eslamifar M, Khezri K, et al. Review on the Use of Kojic Acid — A Skin-Lightening Ingredient. Cosmetics. 2022;9(3):64. | 10.3390/cosmetics9030064 | high | Review on the Use of Kojic Acid—A Skin-Lightening Ingredient |
kojic-acid | Kojic Acid | 3 | Nakagawa M, Kawai K, Kawai K. Contact allergy to kojic acid in skin care products. Contact Dermatitis. 1995;32(1):9-13. | 10.1111/j.1600-0536.1995.tb00832.x | high | Contact allergy to kojic acid in skin care products |
larazotide | Larazotide (AT-1001, Larazotide Acetate) | 0 | Slifer ZM, Krishnan BR, Madan J, Blikslager AT. Larazotide acetate: a pharmacological peptide approach to tight junction regulation. Am J Physiol Gastrointest Liver Physiol. 2021 (mechanism; zonulin/MLCK). | 10.1152/ajpgi.00386.2020 | high | Larazotide acetate: a pharmacological peptide approach to tight junction regulation |
larazotide | Larazotide (AT-1001, Larazotide Acetate) | 3 | Fasano A, et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet. 2000 (the zonulin concept). Porcine ischemia tight-junction repair (2021). (No FDA approval as of 2026; celiac program halted.) | 10.1016/s0140-6736(00)02169-3 | high | Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease |
ll-37 | LL-37 (Cathelicidin) | 1 | Lande R, et al. Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA. (LL-37 + self-DNA → TLR9/pDC); LL-37 as psoriasis T-cell autoantigen. | 10.1002/eji.201344277 | high | Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self‐DNA |
matrixyl | Matrixyl (Palmitoyl Pentapeptide-4) | 0 | Robinson LR, Fitzgerald NC, Doughty DG, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005. (anchor RCT, n=93) | 10.1111/j.1467-2494.2005.00261.x | high | Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin<sup>1</sup> |
matrixyl | Matrixyl (Palmitoyl Pentapeptide-4) | 1 | Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. Int J Cosmet Sci. 2000. (Sederma origin) | 10.1046/j.1467-2494.2000.00010.x | high | Biologically active peptides: from a laboratory bench curiosity to a functional skin care product |
melanotan-ii | Melanotan II | 2 | Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides. 2005. | 10.1016/j.peptides.2005.01.023 | high | Discovery that a melanocortin regulates sexual functions in male and female humans |
mots-c | MOTS-c | 0 | Lee C, Zeng J, Drew BG, … Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. (discovery paper) | 10.1016/j.cmet.2015.02.009 | high | The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance |
naringenin | Naringenin | 0 | Martinez RM, et al. Topical Formulation Containing Naringenin: Efficacy against Ultraviolet B Irradiation-Induced Skin Inflammation and Oxidative Stress in Mice. PLOS ONE. 2016. | 10.1371/journal.pone.0146296 | high | Topical Formulation Containing Naringenin: Efficacy against Ultraviolet B Irradiation-Induced Skin Inflammation and Oxidative Stress in Mice |
naringenin | Naringenin | 2 | Kim HK, et al. Inhibitory effect of naringenin on LPS-induced skin senescence by SIRT1 regulation in HDFs. Biomedical Dermatology. 2018. | 10.1186/s41702-018-0035-6 | high | Inhibitory effect of naringenin on LPS-induced skin senescence by SIRT1 regulation in HDFs |
naringenin | Naringenin | 3 | Martinez RM, et al. Protective Effects of Naringenin against UVB Irradiation and Air Pollution-Induced Skin Aging and Pigmentation. Cosmetics MDPI. 2023; 10(3):88. | 10.3390/cosmetics10030088 | high | Protective Effects of Naringenin against UVB Irradiation and Air Pollution-Induced Skin Aging and Pigmentation |
niacinamide | Niacinamide (Vitamin B3) | 0 | Hakozaki T, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002; 147(1):20-31. | 10.1046/j.1365-2133.2002.04834.x | high | The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer |
niacinamide | Niacinamide (Vitamin B3) | 1 | Bissett DL, et al. Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin. Int J Cosmet Sci. 2004; 26(5):231-8. | 10.1111/j.1467-2494.2004.00228.x | high | Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin<sup>1</sup> |
niacinamide | Niacinamide (Vitamin B3) | 3 | Marques C, et al. Mechanistic Basis and Clinical Evidence for the Applications of Nicotinamide (Niacinamide) to Control Skin Aging and Pigmentation. Antioxidants (Basel). 2021; PMC8389214. | 10.3390/antiox10081315 | high | Mechanistic Basis and Clinical Evidence for the Applications of Nicotinamide (Niacinamide) to Control Skin Aging and Pigmentation |
niacinamide | Niacinamide (Vitamin B3) | 5 | Topical Niacinamide in Daily Skincare: A 3-Week Real-World Cosmetic Study. Appl Sci. 2025; 15(17):9729. | 10.3390/app15179729 | high | Topical Niacinamide in Daily Skincare: A 3-Week Real-World Cosmetic Study |
noopept | Noopept (Omberacetam) | 1 | Ostrovskaya RU, et al. Noopept stimulates NGF and BDNF expression in rat hippocampus. Bull Exp Biol Med. 2008; (neuroprotection in an AD cellular model — apoptosis/tau). J Biomed Sci. 2014. | 10.1007/s10517-008-0297-x | high | Noopept stimulates the expression of NGF and BDNF in rat hippocampus |
pramlintide | Pramlintide (Symlin) | 1 | Cooper GJS, et al. Purification and characterization of a peptide from amyloid-rich pancreas of type-2 diabetics (amylin). PNAS. 1987 (discovery). | 10.1073/pnas.84.23.8628 | high | Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. |
pramlintide | Pramlintide (Symlin) | 4 | Long-acting amylin-related peptides for obesity and T2D. (2026 review) — pramlintide as the first AMYR agonist, second-generation successors. | 10.1016/j.peptides.2026.171480 | high | Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes |
pt-141 | PT-141 (Bremelanotide) | 0 | Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides. 2005. | 10.1016/j.peptides.2005.01.023 | high | Discovery that a melanocortin regulates sexual functions in male and female humans |
rapamycin | Rapamycin (Sirolimus) | 0 | Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009 (NIA ITP; 3-lab replication; late-life start; the field-defining result). | 10.1038/nature08221 | high | Rapamycin fed late in life extends lifespan in genetically heterogeneous mice |
rapamycin | Rapamycin (Sirolimus) | 3 | Roark KM, Iffland PH. Rapamycin for longevity: pros, cons, future perspectives. Front Aging 2025; PEARL RCT (weekly dosing safety; longevity endpoints not met). (Approved immunosuppressant; longevity use off-label and unproven in humans as of 2026.) | 10.3389/fragi.2025.1628187 | high | Rapamycin for longevity: the pros, the cons, and future perspectives |
retinol | Retinol (Vitamin A) | 0 | Kligman AM, Grove GL, Hirose R, Leyden JJ. Topical tretinoin for photoaged skin. J Am Acad Dermatol. 1986; 15(4 Pt 2):836-59. | 10.1016/s0190-9622(86)70242-9 | high | Topical tretinoin for photoaged skin |
retinol | Retinol (Vitamin A) | 3 | Kikuchi K, Suetake T, Kumasaka N, Tagami H. Improvement of photoaged facial skin in middle-aged Japanese females by topical retinol (vitamin A alcohol): a vehicle-controlled, double-blind study. J Dermatolog Treat. 2009; 20(5):276-81. | 10.1080/09546630902973987 | high | Improvement of photoaged facial skin in middle-aged Japanese females by topical retinol (vitamin A alcohol): A vehicle-controlled, double-blind study |
retinol | Retinol (Vitamin A) | 4 | Draelos ZD, et al. A Double-Blind, Comparative Clinical Study of Newly Formulated Retinol Serums vs Tretinoin Cream in Escalating Doses. J Drugs Dermatol. 2020; 19(6):625-31. doi:10.36849/JDD.2020.5085. | 10.36849/jdd.2020.5085 | high | A Double-Blind, Comparative Clinical Study of Newly Formulated Retinol Serums vs Tretinoin Cream in Escalating Doses: A Method for Rapid Retinization With Minimized Irritation |
retinol | Retinol (Vitamin A) | 5 | Zasada M, Budzisz E, Erkiert-Polguj A. A Clinical Anti-Ageing Comparative Study of 0.3 and 0.5% Retinol Serums. Skin Pharmacol Physiol. 2020; 33(2):102-116. | 10.1159/000508168 | high | A Clinical Anti-Ageing Comparative Study of 0.3 and 0.5% Retinol Serums: A Clinically Controlled Trial |
retinol | Retinol (Vitamin A) | 6 | Motamedi M, Chehade A, Sanghera R, Grewal P. A Clinician's Guide to Topical Retinoids. J Cutan Med Surg. 2022; 26(1):71-78. doi:10.1177/12034754211035091. | 10.1177/12034754211035091 | high | A Clinician’s Guide to Topical Retinoids |
retinol | Retinol (Vitamin A) | 7 | Siddiqui MA, Ali Z, Bilal M, et al. Comparative efficacy of topical interventions for facial photoaging: a network meta-analysis. Sci Rep. 2025 (23 RCTs, n=3,905). | 10.1038/s41598-025-12597-0 | high | Comparative efficacy of topical interventions for facial photoaging: a network meta-analysis |
retinol | Retinol (Vitamin A) | 8 | Xie Y, et al. Tretinoin for Photodamaged Facial Skin: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Dermatol Pract Concept. 2025 (8 RCTs, n=1,361; comparator context for retinol). | 10.5826/dpc.1504a5172 | high | Tretinoin for Photodamaged Facial Skin: Systematic Review and Meta-Analysis of Randomized Controlled Trials |
retinol | Retinol (Vitamin A) | 9 | Scientific Committee on Consumer Safety (SCCS). Opinion on the safety of Vitamin A (retinol, retinyl acetate, retinyl palmitate) in cosmetic products. SCCS/1639/21. European Commission. | 10.1016/j.yrtph.2016.11.017 | high | Opinion of the Scientific Committee on Consumer Safety (SCCS) – Final version of the Opinion on Vitamin A (retinol, retinyl acetate and retinyl palmitate) in cosmetic products |
slu-pp-332 | SLU-PP-332 (ERR agonist / "exercise mimetic") | 0 | Billon C, et al. Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity. ACS Chem Biol. (the discovery/mechanism). | 10.1021/acschembio.2c00720 | high | Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity |
slu-pp-915 | SLU-PP-915 | 0 | Billon C, Appourchaux K, Côté I, Burris TP. An orally active estrogen receptor–related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther. 2026;393(1):103787 (the defining paper: oral activity, distinct scaffold, comparable efficacy at lower dose, Ddit4). | 10.1016/j.jpet.2025.103787 | high | An orally active estrogen receptor–related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity |
slu-pp-915 | SLU-PP-915 | 1 | Billon C, et al. A synthetic ERR agonist alleviates metabolic syndrome. J Pharmacol Exp Ther. 2024 (class metabolic effects). | 10.1124/jpet.123.001733 | high | A Synthetic ERR Agonist Alleviates Metabolic Syndrome |
squalane | Squalane | 0 | Kim SK, Karadeniz F. Biological importance and applications of squalene and squalane. Adv Food Nutr Res. 2012; 65:223-33. | 10.1016/b978-0-12-416003-3.00014-7 | high | Biological Importance and Applications of Squalene and Squalane |
squalane | Squalane | 1 | Sethi A, Kaur T, Malhotra SK, Gambhir ML. Moisturizers: The Slippery Road. Indian J Dermatol. 2016; 61(3):279-87. | 10.4103/0019-5154.182427 | high | Moisturizers: The slippery road |
squalane | Squalane | 2 | Pappas A. Epidermal surface lipids. Dermatoendocrinol. 2009; 1(2):72-76 (sebum squalene context). | 10.4161/derm.1.2.7811 | high | Epidermal surface lipids |
squalane | Squalane | 3 | Huang ZR, Lin YK, Fang JY. Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology. Molecules. 2009; 14(1):540-54. | 10.3390/molecules14010540 | high | Biological and Pharmacological Activities of Squalene and Related Compounds: Potential Uses in Cosmetic Dermatology |
ss-31 | SS-31 (Elamipretide) | 3 | Siegel MP, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal-muscle performance in aged mice. Aging Cell. 2013; Campbell MD, et al. Free Radic Biol Med. 2019. | 10.1111/acel.12102 | high | Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice |
ss-31 | SS-31 (Elamipretide) | 4 | Elamipretide mechanistic review — first cardiolipin-directed mitochondrial therapeutic approved under accelerated approval. Drug Discov Ther. 2026. | 10.5582/ddt.2025.01111 | high | Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval |
survodutide | Survodutide (BI 456906) | 2 | Sanyal AJ, et al. A Phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391:311–319. | 10.1056/nejmoa2401755 | high | A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis |
syn-ake | Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate) | 0 | McArdle JJ, Lentz TL, Witzemann V, et al. Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor. J Pharmacol Exp Ther. 1999 (the toxin pharmacology behind it). | 10.1016/s0022-3565(24)38167-4 | high | Waglerin-1 Selectively Blocks the Epsilon Form of the Muscle Nicotinic Acetylcholine Receptor |
syn-ake | Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate) | 2 | Debono J, et al. Viper venom botox: the molecular origin and evolution of the waglerin peptides used in anti-wrinkle skin cream. J Mol Evol (biomimetic origin). | 10.1007/s00239-016-9764-6 | high | Viper Venom Botox: The Molecular Origin and Evolution of the Waglerin Peptides Used in Anti-Wrinkle Skin Cream |
tb-500 | TB-500 (Thymosin Beta-4 fragment) | 0 | Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. (Tβ4 biology review.) | 10.1016/j.molmed.2005.07.004 | high | Thymosin β: actin-sequestering protein moonlights to repair injured tissues |
tb-500 | TB-500 (Thymosin Beta-4 fragment) | 3 | Thymosin Beta-4 and TB-500 in tissue healing and musculoskeletal repair: a scoping review. Appl Sci. 2026. | 10.20944/preprints202605.1124.v1 | high | Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review |
tesofensine | Tesofensine | 0 | Astrup A, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-1913 (Phase 2; ~2× era's drugs; HR +~7 bpm). | 10.1016/s0140-6736(08)61525-1 | high | Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial |
tesofensine | Tesofensine | 2 | Sjödin A, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite… Int J Obes 2010 (↑energy expenditure + ↓appetite; mechanism "unresolved"). | 10.1038/ijo.2010.87 | high | The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men |
Vallydia Ingredient-Evidence Register
An open, evidence-graded reference dataset of 85 cosmetic and research ingredients — peptides, small molecules, proteins and blends — published by Vallydia under CC-BY-4.0.
Most ingredient databases tell you what a compound is. This one tells you how good the evidence actually is, outcome by outcome, and says so honestly when the answer is "we don't know" or "it was tested and it failed".
- Per-outcome A–F evidence grades — a compound can be
Bfor one outcome andFfor another. 456 graded outcome rows. - DOI-verified citations — 117 citations resolved to a DOI with a verified title. This is the credibility spine of the dataset.
- Machine-readable cosmetic-claims maps — for each cosmetic ingredient, the claims that may be made and the claims that must not be. 246 claim rows.
- Legal status by region (INT / EU / US / UK) and WADA prohibited status.
- Chemical identifiers — CAS, PubChem CID, InChIKey, SMILES — each with an explicit confidence level and provenance. Where no confident match exists, the field is blank on purpose.
- Molecular structure images rendered from those identifiers, correct by construction.
Scope, and what is deliberately absent
This is an appearance-and-evidence reference. It contains no dosing, no administration or reconstitution information, and no commerce data — not in any field, and none is introduced by the generator. Research and injectable compounds (GLP-1 analogs, BPC-157, melanotan, and so on) are included as reference entries with their honest grades and legal status, never framed as usable or obtainable.
This is not medical advice. The grades are Vallydia's own evidence assessment, not third-party certification or peer review (reviewer_status is unassigned on every row, and we say so rather than implying a review that did not happen).
Dataset summary
| Compounds | 85 |
| Classes | peptide (53), small_molecule (23), blend (5), protein (3), polysaccharide (1) |
| Graded outcome rows | 456 (97 intentionally ungraded — see below) |
| Cosmetic ingredients | 21, with 246 permitted/forbidden claim rows |
| Legal-status rows | 132 |
| Cited sources | 373, of which 117 are DOI-verified across 50 compounds |
| WADA-prohibited | 19 |
| Confident chemical identifiers | 64 of 85 (21 honestly blank) |
| Structure images | 42 2D structures + 22 large-molecule data cards |
Supported tasks
Evidence-grade classification, evidence-grounded question answering, regulatory-claim checking (which claims are permissible for a given cosmetic ingredient), and retrieval-augmented generation over data/corpus.jsonl.
Languages
English (en).
Dataset structure
Canonical, lossless
data/compounds.jsonl— one JSON object per compound with the full nested structure, including the parsed Markdown body (body_sections) and a raw copy (body_markdown). This is the master file and the primary RAG-ingestion format.data/compounds.json— the same content as a single JSON array.
Flat table
data/compounds.csv— one row per compound: scalar core plus|-joined lists, andbest_outcome_grade/worst_outcome_gradecomputed over the non-null grades.
Long / tidy tables (the analytical heart)
data/grades.csv— one row per compound × outcome.data/legal_status.csv— one row per compound × region.data/citations.csv— the DOI provenance table, joined back to the source text.data/cosmetic_claims.csv— permitted and forbidden claim wordings per cosmetic ingredient.data/identifiers.csv— chemical identifiers with confidence and provenance.
Parquet mirrors — data/parquet/*.parquet for all of the above (Hugging Face auto-generates Croissant JSON-LD from these).
Retrieval corpus
data/corpus.jsonl— one record per compound:{slug, name, title, url, text}, wheretextis a natural-language rendering of the identity, the per-outcome grades, the legal status and the caveats. Every record carries itshttps://vallydia.com/compound/<slug>URL so a citation resolves back to the source.
Images — images/structures/<slug>.svg (+ .png) and images/MANIFEST.csv, which carries mandatory factual alt_text for every image.
Full field-by-field documentation: DATA_DICTIONARY.md.
The grading scale
Two axes: consistency of evidence × magnitude/quality of effect.
| Grade | Meaning |
|---|---|
| A | Strong, consistent human evidence |
| B | Good human evidence, smaller or formulation-dependent effect |
| C | Mixed or limited human evidence |
| D | Weak — mechanistic or very small studies only |
| F | Either untested/unproven, or tested and failed — two different meanings that share a letter |
null |
The row is not an efficacy claim at all (safety and skin-penetration rows, for instance). Carried as null; never coerced into a letter. |
Grades are assigned per outcome, not per compound. overall_grade reflects the leading, best-supported application, graded honestly downward and never up. See METHODOLOGY.md and vallydia.com/methodology.
Chemical identifiers, and why some are blank
Identifiers are resolved against PubChem by exact name/synonym match. A wrong identifier is worse than a blank one in an evidence dataset, so the rule is: no confident, unambiguous match → blank field and identifier_confidence: none. The 21 blanks are blends, stacks, multi-component biologics and proprietary analogs that have no single structure to point at. Where an ambiguity is real, it is recorded rather than resolved by guesswork — see entity_note in identifiers.csv (GHK-Cu is the live example: PubChem's record is the free tripeptide ligand, not the copper(II) complex, and the dataset and the image alt-text both say so).
Structure images are rendered only from high-confidence SMILES. Molecules too large for an honest 2D depiction (large peptides, GLP-1-class analogs) get a factual data card instead of an unreadable hairball.
Dataset creation
Curation rationale. Vallydia maintains an evidence-graded ingredient register because the cosmetic and research-compound market is dominated by claims that outrun their evidence. Publishing the register as open data is the most direct way to say: here is our evidence assessment — audit it.
Source data. Published literature synthesized by Vallydia into the compound register at vallydia.com. The dataset is generated from that register by build/generate_dataset.py — it is not hand-written, and re-running the generator on the same source reproduces it byte-for-byte.
Annotations. The A–F grades and the cosmetic-claims maps are produced by Vallydia. reviewer_status is unassigned throughout: no external reviewer has signed off, and the dataset does not pretend otherwise.
Considerations for using the data
- Not medical advice, and not a dosing reference. Appearance and evidence context only.
- Grades are an assessment, not a measurement. They encode a judgment about a literature base; reasonable experts may grade differently. The
base,effectandcaveatfields exist so you can check the reasoning rather than take the letter on faith. - Coverage bias. The register covers compounds Vallydia's audience actually asks about — cosmetic actives and popular research peptides. It is not a systematic sample of chemical space.
- Literature bias. Grades inherit the biases of the published literature: small samples, industry-funded cosmetic trials, and publication bias toward positive findings. The
caveatfield records these where they are known. - Regulatory data ages.
legal_statusandstatus_notereflect the date inlast_updated. Verify anything regulatory against the primary source before relying on it.
Usage
import pandas as pd
compounds = pd.read_parquet("data/parquet/compounds.parquet")
grades = pd.read_parquet("data/parquet/grades.parquet")
# Cosmetic ingredients with at least one A-graded outcome
best = grades[grades.grade == "A"].merge(
compounds[compounds.is_cosmetic][["slug", "name"]], on="slug"
)
from datasets import load_dataset
ds = load_dataset("vallydia/ingredient-evidence-register", "grades")
More in examples/.
License and attribution
CC-BY-4.0. You may use, remix and redistribute this data, including commercially, provided you give attribution.
Data: Vallydia Ingredient-Evidence Register (https://vallydia.com), CC-BY-4.0.
Citation
Cite the concept DOI — it always resolves to the latest version:
Bilenko, J. (2026). Vallydia Ingredient-Evidence Register (Version 1.0.0) [Data set]. Vallydia. https://doi.org/10.5281/zenodo.21364453
@dataset{vallydia_ingredient_evidence_register,
title = {Vallydia Ingredient-Evidence Register},
author = {Bilenko, Jacob},
year = {2026},
publisher = {Vallydia},
version = {1.0.0},
doi = {10.5281/zenodo.21364453},
url = {https://vallydia.com},
note = {CC-BY-4.0}
}
Maintained by Vallydia · Methodology · Datasheet · Data dictionary
- Downloads last month
- 18